Please Wait.....
Report
Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-13 I 160 Pages I EMR Inc.
Africa Contraceptive Drugs and Devices Market Report and Forecast 2024-2032
Africa Contraceptive Drugs and Devices Market Outlook
The Africa contraceptive drugs and devices market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by trend towards the use of long-acting reversible contraceptives (LARCs) like IUDs and contraceptive implants across the region.
Contraceptive Drugs and Devices: Introduction
Contraceptive drugs and devices are methods used to prevent pregnancy. Contraceptive drugs, such as birth control pills, patches, and injections, typically use hormones to inhibit ovulation or alter cervical mucus. Devices, like condoms, diaphragms, intrauterine devices (IUDs), and contraceptive implants, create physical or chemical barriers to prevent sperm from reaching an egg. These methods vary in form, effectiveness, and duration of action, offering individuals options to choose based on their health, convenience, and family planning goals.
Key Trends in the Africa Contraceptive Drugs and Devices Market
There's a noticeable trend towards the use of Long-Acting Reversible Contraceptives (LARCs) like IUDs and contraceptive implants. These methods are gaining popularity due to their efficacy, ease of use, and long duration, reducing the need for frequent administration or user compliance.
The market is witnessing significant technological advancements and innovation in contraceptive products. This includes the development of contraceptives with fewer side effects, non-hormonal options, and user-friendly designs. There's also a focus on developing digital platforms and mobile applications for education, reminders, and tracking fertility, enhancing user engagement and compliance.
There's a global push to increase awareness of contraceptive options and sexual health education, particularly in emerging economies. Governments and non-profit organizations are working to improve accessibility and affordability of contraceptive drugs and devices, aiming to reduce the incidence of unintended pregnancies and support family planning initiatives.
The market is observing a shift towards personalized contraception, where individuals choose methods based on their lifestyle, health status, and future fertility intentions. Healthcare providers are focusing more on personalized consultations and offering a broader range of contraceptive options to meet individual needs.
Regulatory policies and ethical considerations continue to shape the contraceptive drugs and devices market. Changes in healthcare policies, funding for family planning services, and product approvals have significant impacts on market dynamics. There's also an ongoing dialogue about reproductive rights and access to contraception, influencing public perception and the adoption of contraceptive methods.
Africa Contraceptive Drugs and Devices Market Segmentation
Market Breakup by Product
- Drugs
o Oral Contraceptive Pills
o Injectable Contraceptives
o Topical Contraceptives
- Devices
o Condoms
o Diaphragms
o Cervical Caps
o Sponges
o Vaginal Ring
o Intra Uterine Devices (IUD)
o Others
- Others
Market Breakup by Gender
- Male
- Female
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Clinics
- Online Channel
- Public Channel and NGOs
- Others
Africa Contraceptive Drugs and Devices Market Overview
In Africa, the contraceptive drugs and devices market is evolving, influenced by increasing awareness of family planning and reproductive health. Efforts by governments and international organizations to promote sexual and reproductive health education are driving the demand for contraceptive solutions. The market shows a preference for long-acting reversible contraceptives (LARCs) like implants and IUDs, due to their efficacy and longer duration of action. However, challenges such as cultural attitudes, access to healthcare services, and affordability impact the adoption of contraceptive methods. Initiatives aimed at improving healthcare infrastructure, reducing the cost of contraceptives, and empowering women through education are key factors shaping the market's growth in the region.
Africa Contraceptive Drugs and Devices Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Merck & Co. Inc.
- Mylan N.V.
- Pfizer Inc.
- Bayer AG
- AbbVie
- Lupin Limited
- Teva Pharmaceutical Industries Ltd
- Medicines360
- Durex
- Mankind Pharma
- Johnson & Johnson
- Gabler Medical
- Sinapi Biomedical
- Church & Dwight
- CooperSurgical
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Africa Contraceptive Drugs and Devices Market Overview
3.1 Africa Contraceptive Drugs and Devices Market Historical Value (2017-2023)
3.2 Africa Contraceptive Drugs and Devices Market Forecast Value (2024-2032)
4 Africa Contraceptive Drugs and Devices Market Landscape
4.1 Africa Contraceptive Drugs and Devices Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.2 Africa Contraceptive Drugs and Devices Product Landscape
4.2.1 Analysis by Product
4.2.2 Analysis by Gender
5 Africa Contraceptive Drugs and Devices Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Africa Contraceptive Drugs and Devices Market Segmentation
6.1 Africa Contraceptive Drugs and Devices Market by Product
6.1.1 Market Overview
6.1.2 Drugs
6.1.2.1 Oral Contraceptive Pills
6.1.2.2 Injectable Contraceptives
6.1.2.3 Topical Contraceptives
6.1.3 Devices
6.1.3.1 Condoms
6.1.3.2 Diaphragms
6.1.3.3 Cervical Caps
6.1.3.4 Sponges
6.1.3.5 Vaginal Ring
6.1.3.6 Intra Uterine Devices (IUD)
6.1.3.7 Others
6.1.4 Others
6.2 Africa Contraceptive Drugs and Devices Market by Gender
6.2.1 Market Overview
6.2.2 Male
6.2.3 Female
6.3 Africa Contraceptive Drugs and Devices Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacy
6.3.3 Retail Pharmacy
6.3.4 Clinics
6.3.5 Online Channel
6.3.6 Public Channel and NGOs
6.3.7 Others
7 Patent Analysis
7.1 Analysis by Type of Patent
7.2 Analysis by Publication year
7.3 Analysis by Issuing Authority
7.4 Analysis by Patent Age
7.5 Analysis by CPC Analysis
7.6 Analysis by Patent Valuation
7.7 Analysis by Key Players
8 Grants Analysis
8.1 Analysis by year
8.2 Analysis by Amount Awarded
8.3 Analysis by Issuing Authority
8.4 Analysis by Grant Application
8.5 Analysis by Funding Institute
8.6 Analysis by NIH Departments
8.7 Analysis by Recipient Organization
9 Clinical Trials Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
10 Funding & Investment Analysis
10.1 Analysis by Funding Instances
10.2 Analysis by Type of Funding
10.3 Analysis by Funding Amount
10.4 Analysis by Leading Players
10.5 Analysis by Leading Investors
10.6 Analysis by Geography
11 Partnership and Collaborations Analysis
11.1 Analysis by Partnership Instances
11.2 Analysis by Type of Partnership
11.3 Analysis by Leading Players
11.4 Analysis by Geography
12 Regulatory Framework
13 Supplier Landscape
13.1 Merck & Co. Inc.
13.1.1 Financial Analysis
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.1.5 Certifications
13.2 Mylan N.V.
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Pfizer Inc.
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Bayer AG
13.4.1 Financial Analysis
13.4.2 Financial Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 AbbVie
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Lupin Limited
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Teva Pharmaceutical Industries Ltd
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Medicines360
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Durex
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Mankind Pharma
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Johnson & Johnson
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
13.12 Gabler Medical
13.12.1 Financial Analysis
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.12.5 Certifications
13.13 Sinapi Biomedical
13.13.1 Financial Analysis
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
13.13.5 Certifications
13.14 Church & Dwight
13.14.1 Financial Analysis
13.14.2 Product Portfolio
13.14.3 Demographic Reach and Achievements
13.14.4 Mergers and Acquisitions
13.14.5 Certifications
13.15 CooperSurgical
13.15.1 Financial Analysis
13.15.2 Product Portfolio
13.15.3 Demographic Reach and Achievements
13.15.4 Mergers and Acquisitions
13.15.5 Certifications
14 Africa Contraceptive Drugs and Devices Market - Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security